Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page
Price
Target price
€15.08

€15.08

0.490%
0.09
0.490%
€20.50

€20.50

 
Latest predictions
-
24.09.20
€20.00
01.08.20
buy
-
20.07.20
buy
€21.00
07.06.20
buy
€29.50
20.08.18
buy
€16.53
01.12.17
buy
Your prediction

GlaxoSmithKline plc Stock

The GlaxoSmithKline plc stock is trending slightly upwards today, with an increase of €0.090 (0.490%) compared to yesterday's price.
Currently there is a rather positive sentiment for GlaxoSmithKline plc with 5 Buy predictions and 1 Sell predictions.
As a result the target price of €20.00 shows a positive potential of 32.626% compared to the current price of €15.08 for GlaxoSmithKline plc.

Pros and Cons of GlaxoSmithKline plc in the next few years

Pros
?
Brand
?
Growth compared to competition
?
Non-cyclic/Cyclic
Cons
?
Worthwhile Investment for the next years
?
Conscious of the environment
?
Market Position
Tell us your opinion to access the 'Wisdom of the Crowds'

Comments

Buy GlaxoSmithKline plc

Show more
You may not comment on this article as you either did not confirm your account yet or were blocked. If you think this is a mistake please contact us. Show more

Other discussions about GlaxoSmithKline plc Stock

Trading GlaxoSmithKline plc

Trading GlaxoSmithKline plc

New thread Forum

News

FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma


GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed